title: Clinical features of patients with esophageal and second primary cancers.
abstract: BACKGROUND
  The prevalence of esophageal cancer (EC) with second primary cancers (SPC) is increasing worldwide. This study was aimed to understand the clinical features of EC patients with SPC in the Taiwanese population.
  
  
  METHODS
  Clinical and laboratory data for 180 EC patients with or without SPC were collected between January 2009 and December 2013. Information on treatment approaches, location of SPCs and ABO blood type were also collected and stratified.
  
  
  RESULTS
  The most common SPC in EC patients was hypopharyngeal cancer, followed by laryngeal cancer and hepatocellular carcinoma in our study. Malignancies of colon, prostate and lung were also found. There was a significant higher portion of blood type A in the EC patients with SPC compared with those without (42.4% vs 19.5%, P=0.006).
  
  
  CONCLUSIONS
  The frequency and SPC site distribution and blood type A should be considered in clinical evaluation of EC patients with a high risk of developing SPC in the Taiwanese population.
authors.affiliation: Department of General Surgery, Far Eastern Memorial Hospital, New Taipei, Taiwan E-mail : klatskin@mail.femh.org.tw.
authors.forename: Huang-Wen
authors.initials: HW
authors.lastname: Tsai
authors.forename: Chih-Chun
authors.initials: CC
authors.lastname: Chang
authors.forename: Jen-Tang
authors.initials: JT
authors.lastname: Sun
authors.forename: Ching-Biau
authors.initials: CB
authors.lastname: Liou
authors.forename: Hsiu-Chen
authors.initials: HC
authors.lastname: Lin
authors.forename: I-Hsin
authors.initials: IH
authors.lastname: Lin
authors.forename: Yun-Chieh
authors.initials: YC
authors.lastname: Yu
authors.forename: Wei-Ling
authors.initials: WL
authors.lastname: Weng
authors.forename: Ka-I
authors.initials: KI
authors.lastname: Leong
authors.forename: Tzung-Hai
authors.initials: TH
authors.lastname: Yen
authors.forename: Jiann-Ming
authors.initials: JM
authors.lastname: Wu
mesh_terms: D003131:Combined Modality Therapy; D004938:Esophageal Neoplasms / Q000473:pathology* / Q000628:therapy; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016609:Neoplasms, Second Primary / Q000453:epidemiology* / Q000473:pathology*; D011379:Prognosis; D013624:Taiwan / Q000453:epidemiology